Navigation Links
Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients

DENVER, Sept. 15 /PRNewswire/ -- On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

Dr. Bruner is a past president of the American Society of Bariatric Physicians (ASBP) and will speak to the committee on behalf of the Society's nearly 1,300 members throughout the U.S.  ASBP's physicians know from long experience that obesity can be a lifelong, chronic illness, which ultimately can produce very serious health risks and which can lower the quality of life of those afflicted.  

With recent obesity costs topping $147 billion per year, it is imperative that doctors be better equipped to treat obesity.  Research has shown that medical intervention can assist with weight loss and maintenance, and that weight loss can reverse or retard the development of diabetes, hypertension, sleep apnea and numerous other seriously harmful consequences of obesity.

Patients with obesity have few treatment options. While new obesity drugs are reviewed with great caution due to unexpected adverse reactions of past drugs, there is every reason to be confident that the clinical trials for Lorcaserin have adequately identified the relevant risks. Dr. Bruner, in speaking on behalf of the ASBP, will encourage the FDA advisory committee to consider the demonstrated effectiveness and benefits of this drug as thoroughly as it considers any risks.

About the ASBP

Founded in 1950, the ASBP is the oldest medical association focused on the education and training of medical professionals treating and managing obese patients and associated diseases. The ASBP is a collaborative organization that provides its members practical information and business tools to implement a successful medical bariatric practice. For more information about the ASBP, visit

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
8. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
9. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
10. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
Breaking Medicine News(10 mins):